Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

Other

4

Investigational

1

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Motilin receptor

1

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Phase II

1

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

Unknown

5

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Gastroparesis

1

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

1

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

GlaxoSmithKline

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

5

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

5

EPA CompTox

5

FDA UNII

5

PUBCHEM

5

NSC

4

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Principal Form

4

Salts, Hydrates, Esters, etc.

1

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 5 of 5 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

CAMICINAL

3C8348951H

Export Data
Search for Structure

Status:

Investigational

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Motilin receptor

Conditions:

GlaxoSmithKline is developing Camicinal (GSK 962040), an oral motilin receptor agonist for the treatment of gastroparesis. Camicinal is being evaluated in phase II for diabetic gastroparesis and gastroparesis. Camicinal is well tolerated in multiple ...

trials with no serious drug-related adverse events or changes in ECG chemistry when given as a single oral dose of up to 125 mg. Although larger studies are soon to be reported, current evidence shows that adverse events occurred evenly between the placebo and treatment groups, and was generally mild. Camicinal has been previously shown to increase gastric emptying in volunteers after repeat dosing over 14 days with no tolerance effect in patients with gastroparesis and type 1 diabetes. Camicinal meets the criteria of an ideal motilin agonist. The compound activates long-lasting cholinergic contractility at low doses in the antrum with greater efficacy than current therapeutic options.

4-(TRIFLUOROMETHYL)ANILINE

RQJ623MB8G

Export Data
Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ACHIRAL)

3-FLUOROPHENOL

T7OMA38487

Export Data
Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ACHIRAL)

3-TRIFLUOROMETHYLANILINE

Z1RWM538YN

Export Data
Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ACHIRAL)

3-(Trifluoromethyl)aniline hydrochloride

D8M2XGK72F

Export Data
Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ACHIRAL)

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1